Strategic Advisors LLC Has $232,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Strategic Advisors LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 556 shares of the pharmaceutical company’s stock after acquiring an additional 31 shares during the period. Strategic Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $232,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Venturi Wealth Management LLC increased its position in Vertex Pharmaceuticals by 1.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after buying an additional 24 shares during the last quarter. Nicholas Hoffman & Company LLC. increased its position in Vertex Pharmaceuticals by 3.9% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after buying an additional 24 shares during the last quarter. Hohimer Wealth Management LLC grew its position in shares of Vertex Pharmaceuticals by 0.8% in the fourth quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock valued at $1,193,000 after purchasing an additional 24 shares during the last quarter. Johnson Financial Group Inc. grew its position in shares of Vertex Pharmaceuticals by 2.5% in the fourth quarter. Johnson Financial Group Inc. now owns 1,001 shares of the pharmaceutical company’s stock valued at $407,000 after purchasing an additional 24 shares during the last quarter. Finally, Arthur M. Cohen & Associates LLC grew its position in shares of Vertex Pharmaceuticals by 3.2% in the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock valued at $326,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock traded up $2.98 during mid-day trading on Friday, hitting $473.26. 153,132 shares of the stock were exchanged, compared to its average volume of 1,225,705. The company has a 50-day simple moving average of $450.53 and a 200 day simple moving average of $428.29. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. Vertex Pharmaceuticals Incorporated has a 12 month low of $335.82 and a 12 month high of $486.42. The company has a market capitalization of $122.12 billion, a P/E ratio of 30.52, a P/E/G ratio of 2.44 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion during the quarter, compared to analyst estimates of $2.58 billion. During the same period in the previous year, the business earned $2.67 EPS. Vertex Pharmaceuticals’s revenue was up 13.3% compared to the same quarter last year. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on VRTX shares. StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Argus boosted their price target on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the company a “buy” rating in a research note on Monday, June 17th. Guggenheim boosted their price target on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. Finally, UBS Group cut their price target on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $448.61.

Insider Activity

In other news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total transaction of $1,089,840.00. Following the transaction, the chief marketing officer now directly owns 32,379 shares of the company’s stock, valued at $15,477,162. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total transaction of $1,089,840.00. Following the sale, the chief marketing officer now directly owns 32,379 shares in the company, valued at $15,477,162. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce I. Sachs sold 7,073 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total value of $3,168,704.00. Following the sale, the director now owns 40,000 shares in the company, valued at $17,920,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,366 shares of company stock valued at $13,058,787. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.